10-Q: Polomar Health Services Q1 2026 Update: Revenue Surge, Net Loss Narrows

Polomar Health Services reports a significant revenue increase in Q1 2026 driven by a business model shift, though the company continues to face challenges and substantial doubt about its going concern status.

Summary

• Polomar Health Services reported revenues of $1,005,519 for the three months ended March 31, 2026, a substantial increase from $4,542 in the same period of 2025, attributed to a shift from a retail to a wholesale business model.
• Operating expenses rose by approximately 28% to $557,391 in Q1 2026 from $418,590 in Q1 2025, primarily due to shipping costs, legal/accounting/SEC filing fees, and payroll.
• The net loss for Q1 2026 was $25,377, a significant improvement from a net loss of $456,855 in Q1 2025.
• The company has a working capital deficit of ($1,294,458) as of March 31, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern due to its history of losses, negative cash flows, and insufficient cash to fund operations for the next 12 months.
• Management plans to raise additional capital, invest in pharmacy operations, and explore other business opportunities.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties and insufficient written policies and procedures.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the ongoing going concern issues, material weaknesses in internal controls, and significant legal/contractual risks, despite some positive revenue trends.

Positives

• Significant increase in revenue from $4,542 in Q1 2025 to $1,005,519 in Q1 2026, reflecting a successful business model transition to wholesale.
• Net loss narrowed considerably from $456,855 in Q1 2025 to $25,377 in Q1 2026.
• The company is actively seeking licenses in additional states, expecting to expand prescription medication delivery capabilities.
• The SlimRx trademark received a Notice of Allowance from the USPTO, indicating progress in its weight-loss focused online platform.
• The company has executed contracts with ForHumanity Health, Inc. and CareValidate, Inc. for prescription fulfillment services, anticipating steady growth in this wholesale segment.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern due to a history of losses, negative operating cash flows, and insufficient cash reserves.
• Working capital deficit of ($1,294,458) as of March 31, 2026.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties and insufficient written policies and procedures.
• The company experienced delays in product formulation development, manufacturing due to supply chain issues (now resolved), and logistical challenges.
• ForHumanity Health, Inc. has suspended sales of VigorAir and intends to terminate its agreement, alleging damages exceeding $20,000,000.
• The company's operations are highly dependent on third-party utilization of its compounded drug formulations.

Risks

• Uncertainty of profitability based upon the company's history of losses.
• Legislative or regulatory changes concerning platforms with data about companies.
• Risks related to failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Risks related to operations and uncertainties related to the business plan and strategy.
• Changes in economic conditions.
• Uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement of others' intellectual property.
• Competition.
• Cybersecurity concerns.
• The company has experienced significant delays in bringing licensed products to market, impacting launch dates for inhaled sildenafil, metformin gummy, and inhaled eletriptan.
• ForHumanity Health, Inc. has expressed concerns regarding the efficacy of the inhaled sildenafil product and has elected not to pursue an agreement to market the metformin gummy.
• ForHumanity Health, Inc. has advised the company of their intent to terminate and rescind the Product Fulfillment and Distribution Agreement.
• The company is subject to potential litigation from ForHumanity Health, Inc. seeking over $20,000,000 in damages.

Future Outlook

The company expects steady growth in its wholesale prescription fulfillment business over the next twelve to eighteen months as it adds additional customers and fulfillment capacity. The SlimRx online platform is planned for launch in the third quarter of 2026. The company anticipates being able to provide prescription medications in additional U.S. states during the third quarter of 2026. However, the company's ability to continue as a going concern is dependent on raising additional capital.

Management Comments

• The increase in revenues over the previous accounting period was primarily due to the registrants change in its business from a retail to a wholesale business model.
• Operating expenses, which consisted mainly of general and administrative expenses, increased to approximately $557,391 for the three months ended March 31, 2026, from approximately $418,590 for the three months ended March 31, 2025, an approximately 28% increase.
• We recorded a net loss of approximately $25,377 for the three months ended March 31, 2026, as compared with a net loss of approximately $466,855 for the three months ended March 31, 2025, as a result of the expenses incurred and insufficient revenues generated during the period.
• We currently do not have sufficient cash to fund our operations for the next 12 months and we require additional working capital for ongoing operating expenses, which has been funded during the three-month period ended March 31, 2026, by related party loans.
• Management is currently in the process of looking for additional investors.
• Over the next twelve months management plans to raise additional capital and to invest its working capital resources in its existing business and other potential business opportunities.
• Management has identified the following material weaknesses which have caused management to conclude that, as of March 31, 2026, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Industry Context

StockSavvy.ai notes that Polomar Health Services' strategic shift towards a wholesale model and expansion into sterile compounding aligns with broader trends in the specialty pharmacy sector, which is increasingly focused on complex drug formulations and B2B partnerships. The company's efforts to secure licenses and develop online platforms like SlimRx reflect a common strategy to broaden market reach and leverage telehealth trends.

Comparison to Industry Standards

• The revenue growth from $4,542 to over $1 million in a year is a significant positive deviation from typical early-stage specialty pharmacy performance, though it originates from a very low base.
• The company's net loss has narrowed substantially, but the continued net loss and negative operating cash flow are concerning when compared to established, profitable specialty pharmacies.
• The identified material weaknesses in internal controls are a significant concern and are not standard for mature companies in the pharmaceutical sector.
• The reliance on related party debt for working capital is a common characteristic of early-stage companies but is less common for established players who typically access traditional credit lines or equity markets more readily.

Corporate Governance

Legal Proceedings

• ForHumanity Health, Inc. has alleged intentional and fraudulent misrepresentations, demanding $2,000,000 in settlement and claiming damages exceeding $20,000,000.
• The company believes ForHumanity's claims are without merit and intends to issue a Notice of Default if the matter is not resolved.

Related Party Transactions

• Promissory Note and Loan Agreement with Reprise Management, Inc. (Reprise) for up to $700,000, with an outstanding balance of $652,584 as of March 31, 2026.
• Promissory Note and Loan Agreement with CWR 1, LLC (CWR) for up to $250,000 (CWR Note) and later up to $300,000 (CWR Note II), with an outstanding balance of $0 as of March 31, 2026 for CWR Note II.
• Promissory Note and Loan Agreement with Profesco Holdings, LLC (Profesco Note) for up to $200,000, with an outstanding balance of $166,368 as of March 31, 2026. Terrence M. Tierney, CEO, is the sole member and manager of Profesco Holdings.
• Polomar Specialty Pharmacy purchased $122,062.50 worth of WafesilTM from Orion Specialty Labs, LLC, an affiliate of GLD Partners, LP, which is controlled by Dan Gordon.

Stakeholder Impact

• Shareholders: Continued uncertainty regarding the company's going concern status and potential dilution from future capital raises. The Altanine merger could significantly alter ownership structure.
• Creditors: The company's financial condition and going concern issues pose risks to creditors, particularly given the reliance on related party debt.
• Employees: Potential impact on job security due to the going concern issues and the need for cost management. Management compensation is tied to performance and stock options.
• Customers: Potential disruption of services if the company fails to address its financial challenges. The ForHumanity dispute could impact the availability of certain products.
• Suppliers: Potential for delayed payments or supply chain disruptions if the company's financial situation deteriorates.

Next Steps

• Launch of the SlimRx online platform in the third quarter of 2026.
• Expansion of prescription medication delivery capabilities to additional U.S. states during the third quarter of 2026.
• Raising additional capital upon the closing of the Altanine Merger transaction.
• Investing working capital resources in Polomar's pharmacy operations and other potential business opportunities.
• Resolving issues with ForHumanity Health, Inc. regarding product manufacturing, testing delays, marketing challenges, and clinical trials.

Key Dates

Recommendation

While the revenue growth is a positive sign, the company's significant going concern issues, material weaknesses in internal controls, and the potential termination of a key agreement with substantial legal claims outweigh the revenue improvements. The Altanine merger and future capital raises introduce significant uncertainty. A 'hold' recommendation reflects the need for further clarity on the company's ability to overcome its financial and operational challenges before considering a more definitive investment stance.

Keywords

Polomar Health Services, Form 10-Q, Quarterly Report, Specialty Pharmacy, Compounding Pharmacy, GLP-1 Agonists, Revenue Growth, Net Loss, Going Concern, Internal Controls, Altanine Merger, ForHumanity Health, CareValidate